Who has which rare disease? A map of 406 rare diseases across ethnic groups in England
Of 62.5 million people in England, 1.7% had one of 406 rare diseases, and they had more recorded COVID-19 infection (32.8% vs 29.0%).
Who is most at risk, how the disease unfolds, and what the pandemic cost, across millions of people.
Of 62.5 million people in England, 1.7% had one of 406 rare diseases, and they had more recorded COVID-19 infection (32.8% vs 29.0%).
A transformer-based model estimated what would have happened under different blood pressure treatments, using data from over 300,000 patients.
Eight rare diseases carried a clearly higher risk of dying from COVID-19, even after vaccination, in a study covering 331 rare diseases and 58 million people.
Linking eight national NHS datasets, we defined ten COVID-19 stages and mapped how patients moved between them in the first two waves.
In 283 Genomics England participants, rare disease was linked to higher COVID-19 death, especially neurological and neurodevelopmental conditions, though numbers were small.
Two clustering methods using axes of prognosis revealed distinct subgroups of poor outcome, especially among respiratory patients, and predicted membership on admission.
An ensemble that picks the most competent models for each patient beat every individual model across four cohorts in the UK and China.
The NEWS2 score was a weak predictor of severe COVID-19, but adding age and a few routine blood tests improved it across hospitals in the UK, Norway and China.
Hospital activity for cardiovascular disease fell by 60 to 100% during the pandemic, and we estimated tens of thousands of excess deaths in England, direct and indirect.
A simple model using age, sex and routine blood tests worked well in Wuhan but less well in London, where patients were far sicker, showing why external validation matters.
Looking for the formal papers? Every story links to its paper. Browse publications →